Combination of Biosynth Carbosynth and vivitide creates global life sciences platform serving high-growth biopharma and diagnostics end markets

 London, 17 March 2022 - KKR, a leading global investment firm, announced today the closing of its previously announced investment in Biosynth Carbosynth, an innovative life sciences reagents, custom synthesis and manufacturing services company, as well as Biosynth Carbosynth’s acquisition of vivitide, a global provider of custom peptides and antibodies for the life sciences and biotech industry. Existing vivitide owner Ampersand Capital Partners will roll over its entire stake and become a substantial minority shareholder of the combined entity. Together, KKR and Ampersand plan to accelerate the company’s geographic expansion, broaden its capabilities, and expand its product portfolio.

Read full press release here...